casino game logo

The Onion's bid to buy Infowars goes before judge as Alex Jones tries stopping salecasino game logo 。

The Mauritius Ministry of Education, Science and Technology invites Nigerian students to apply for the Mauritius-Africa Scholarship Scheme 2025 Eligible undergraduates and postgraduates can apply for full-time programs at public Higher Education Institutions in Mauritius by February 20, 2025 Applicants must meet specific criteria, including age limits and academic qualifications, and submit a completed application form to the Federal Scholarship Board in Abuja Don't miss out! Join Legit.ng's Sports News channel on WhatsApp now! The Mauritius Ministry of Education, Science and Technology has announced the Mauritius-Africa Scholarship Scheme 2025. This initiative invites eligible Nigerian undergraduate and postgraduate students to apply for the 2025 academic year. Application Procedures To apply, students must complete the application form available at the following websites: PAY ATTENTION: Legit.ng Needs Your Help! Take our Survey Now and See Improvements at LEGIT.NG Tomorrow Mauritius Ministry of Education Higher Education Mauritius Applicants need to have applied for at least one full-time on-campus program at a public Higher Education Institution (HEI) in Mauritius. They can either obtain a conditional offer (letter of admission) or submit an acknowledgement notice from their chosen Mauritian public HEI confirming that their application and fees have been received. Read also Rhodes University announces Andrew W. Mellon Foundation Masters Scholarship Submission Details Candidates must submit the fully completed application form and required documents to the Federal Scholarship Board , Abuja , by February 20, 2025. The eligibility criteria for applicants are as follows: Must be a Nigerian citizen. Undergraduate applicants must be at least 18 years old and not have reached their 26th birthday by January 1, 2026. Postgraduate applicants must not have reached their 40th birthday by January 1, 2026. A health certificate from a recognized government hospital is required. Undergraduates must have a good WAEC result. Masters and PhD applicants must have a minimum of a Second Class Upper (2.1) degree. FG Announces Scholarship Awards for Students Meanwhile, Legit.ng earlier reported that the federal ministry of Education has invited interested and qualified Nigerians to participate in the 2023/24 Nigerian Scholarship Award (NSA) and Education Bursary Award. Read also Top WAEC students 2009: Where is Sephiat Oniyangi and other best 100 candidates now? According to the statement, registration commenced on Tuesday, April 2 and will close on May 13, 2024. This was disclosed by the ministry’s X handle (formerly known as Twitter) @NigEducation on Tuesday, April. PAY ATTENTION: Сheck out news that is picked exactly for YOU ➡️ find the “Recommended for you” block on the home page and enjoy! Source: Legit.ng

ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Dec 9, 2024-- Phreesia, Inc. (NYSE: PHR) (“Phreesia” or the "Company") announced financial results today for the fiscal third quarter ended October 31, 2024. "We are excited about the future here at Phreesia,” said CEO and Co-Founder Chaim Indig. “Our network continues to grow, adoption of our current offerings is increasing, and we are beginning to see the promise of new solutions we are investing in.” Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q3 Fiscal Year 2025 Stakeholder Letter. Fiscal Third Quarter Ended October 31, 2024 Highlights Fiscal Year 2025 Outlook We are narrowing our revenue outlook for fiscal 2025 to a range of $418 million to $420 million from a previous range of $416 million to $426 million, implying year-over-year growth of 17% to 18%. We are updating our Adjusted EBITDA outlook for fiscal 2025 to a range of $34 million to $36 million from a previous range of $26 million to $31 million. Our outlook reflects our strong performance in the fiscal third quarter and our continued focus on margin improvement. We are maintaining our expectation for AHSCs to reach approximately 4,200 for fiscal 2025, compared to 3,601 in fiscal 2024. We are maintaining our expectation for Total revenue per AHSC to increase in fiscal 2025 compared to the $98,944 we achieved in fiscal 2024. Fiscal Year 2026 Outlook We are introducing our revenue outlook for fiscal 2026. We expect revenue to be in the range of $472 million to $482 million. The revenue range provided for fiscal 2026 assumes no additional revenue from potential future acquisitions completed between now and January 31, 2026. We are introducing our Adjusted EBITDA outlook for fiscal 2026. We expect Adjusted EBITDA to be in the range of $78 million to $88 million. The Adjusted EBITDA range provided for fiscal 2026 assumes continued improvement in operating leverage across the Company through focusing on efficiency. We expect AHSCs to reach approximately 4,500 in fiscal 2026. Additionally, we expect Total revenue per AHSC in fiscal 2026 to increase from fiscal 2025. We believe our $81.7 million in cash and cash equivalents as of October 31, 2024, along with cash generated in our normal operations, gives us sufficient flexibility to reach our fiscal 2025 and fiscal 2026 outlook. Additionally, our available borrowing capacity under our credit facility with Capital One provides us with an additional source of capital to pursue future growth opportunities not incorporated into our fiscal 2025 and fiscal 2026 outlook. As of October 31, 2024 we have no borrowings outstanding under our credit facility. Non-GAAP Financial Measures We have not reconciled our Adjusted EBITDA outlook to GAAP Net income (loss) because we do not provide an outlook for GAAP Net income (loss) due to the uncertainty and potential variability of Other (income) expense, net and (Benefit from) provision for income taxes, which are reconciling items between Adjusted EBITDA and GAAP Net income (loss). Because we cannot reasonably predict such items, a reconciliation of the non-GAAP financial measure outlook to the corresponding GAAP measure is not available without unreasonable effort. We caution, however, that such items could have a significant impact on the calculation of GAAP Net income (loss). For further information regarding the non-GAAP financial measures included in this press release, including a reconciliation of GAAP to non-GAAP financial measures and an explanation of these measures, please see “Non-GAAP financial measures” below. Available Information We intend to use our Company website (including our Investor Relations website) as well as our Facebook, X, LinkedIn and Instagram accounts as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Forward Looking Statements This press release includes express or implied statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events or our future financial or operating performance and may contain projections of our future results of operations or of our financial information or state other forward-looking information. These statements include, but are not limited to, statements regarding: our future financial and operating performance, including our revenue, operating leverage, margins, Adjusted EBITDA, cash flows and profitability 3; our ability to finance our plans to achieve our fiscal 2025 and fiscal 2026 outlook with our current cash balance and cash generated in the normal course of business; and our outlook for fiscal 2025 and fiscal 2026, including our expectations regarding revenue, Adjusted EBITDA, AHSCs and Total revenue per AHSC. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, risks associated with: our ability to effectively manage our growth and meet our growth objectives; our focus on the long-term and our investments in growth; the competitive environment in which we operate; our ability to comply with the covenants in our credit agreement with Capital One; changes in market conditions and receptivity to our products and services; our ability to develop and release new products and services and successful enhancements, features and modifications to our existing products and services; our ability to maintain the security and availability of our platform; the impact of cyberattacks, security incidents or breaches impacting our business; changes in laws and regulations applicable to our business model; our ability to make accurate predictions about our industry and addressable market; our ability to attract, retain and cross-sell to healthcare services clients; our ability to continue to operate effectively with a primarily remote workforce and attract and retain key talent; our ability to realize the intended benefits of our acquisitions and partnerships; and difficulties in integrating our acquisitions and investments; and other general, market, political, economic and business conditions (including from the results of the 2024 U.S. presidential and congressional elections and the warfare and/or political and economic instability in Ukraine, the Middle East or elsewhere). The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those listed or described in our filings with the Securities and Exchange Commission (“SEC”), including in our Quarterly Report on Form 10-Q for the fiscal quarter ended October 31, 2024 that will be filed with the SEC following this press release. The forward-looking statements in this press release speak only as of the date on which the statements are made. We undertake no obligation to update, and expressly disclaim the obligation to update, any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. This press release includes certain non-GAAP financial measures as defined by SEC rules. We have provided a reconciliation of those measures to the most directly comparable GAAP measures, with the exception of our Adjusted EBITDA outlook for the reasons described above. Conference Call Information We will hold a conference call on Monday December 9, 2024 at 5:00 p.m. Eastern Time to review our fiscal 2025 third quarter financial results. To participate in our live conference call and webcast, please dial (800) 715-9871 (or (646) 307-1963 for international participants) using conference code number 7404611 or visit the “Events & Presentations” section of our Investor Relations website at ir.phreesia.com . A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days. About Phreesia Phreesia is a trusted leader in patient activation, giving providers, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled approximately 150 million patient visits in 2023—more than 1 in 10 visits across the U.S.—scale that we believe allows us to make meaningful impact. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives efficiency and improves healthcare outcomes. Phreesia, Inc. Consolidated Balance Sheets (in thousands, except share and per share data) October 31, 2024 January 31, 2024 (Unaudited) Assets Current: Cash and cash equivalents $ 81,740 $ 87,520 Settlement assets 25,046 28,072 Accounts receivable, net of allowance for doubtful accounts of $1,468 and $1,392 as of October 31, 2024 and January 31, 2024, respectively 71,408 64,863 Deferred contract acquisition costs 362 768 Prepaid expenses and other current assets 11,017 14,461 Total current assets 189,573 195,684 Property and equipment, net of accumulated depreciation and amortization of $87,861 and $76,859 as of October 31, 2024 and January 31, 2024, respectively 25,973 16,902 Capitalized internal-use software, net of accumulated amortization of $53,210 and $45,769 as of October 31, 2024 and January 31, 2024, respectively 51,322 46,139 Operating lease right-of-use assets 1,656 266 Deferred contract acquisition costs 450 986 Intangible assets, net of accumulated amortization of $7,536 and $4,925 as of October 31, 2024 and January 31, 2024, respectively 29,014 31,625 Goodwill 75,845 75,845 Other assets 1,870 2,879 Total Assets $ 375,703 $ 370,326 Liabilities and Stockholders’ Equity Current: Settlement obligations $ 25,046 $ 28,072 Current portion of finance lease liabilities and other debt 8,866 6,056 Current portion of operating lease liabilities 1,021 393 Accounts payable 15,870 8,480 Accrued expenses 29,080 37,130 Deferred revenue 22,188 24,113 Other current liabilities 7,130 5,875 Total current liabilities 109,201 110,119 Long-term finance lease liabilities and other debt 10,292 5,400 Operating lease liabilities, non-current 840 134 Long-term deferred revenue 199 97 Long-term deferred tax liabilities 446 270 Other long-term liabilities 133 2,857 Total Liabilities 121,111 118,877 Commitments and contingencies Stockholders’ Equity: Preferred stock, undesignated, $0.01 par value - 20,000,000 shares authorized as of both October 31, 2024 and January 31, 2024; no shares issued or outstanding as of both October 31, 2024 and January 31, 2024 — — Common stock, $0.01 par value - 500,000,000 shares authorized as of both October 31, 2024 and January 31, 2024; 59,439,197 and 57,709,762 shares issued as of October 31, 2024 and January 31, 2024, respectively 594 577 Additional paid-in capital 1,094,629 1,039,361 Accumulated deficit (795,106 ) (742,969 ) Accumulated other comprehensive loss (5 ) — Treasury stock, at cost, 1,355,169 shares as of both October 31, 2024 and January 31, 2024 (45,520 ) (45,520 ) Total Stockholders’ Equity 254,592 251,449 Total Liabilities and Stockholders’ Equity $ 375,703 $ 370,326 Phreesia, Inc. Consolidated Statements of Operations (Unaudited) (in thousands, except share and per share data) Three months ended October 31, Nine months ended October 31, 2024 2023 2024 2023 Revenue: Subscription and related services $ 49,363 $ 42,595 $ 144,717 $ 119,783 Payment processing fees 24,704 23,218 77,064 71,102 Network solutions 32,733 25,806 88,351 70,409 Total revenues 106,800 91,619 310,132 261,294 Expenses: Cost of revenue (excluding depreciation and amortization) 17,854 15,529 49,720 44,885 Payment processing expense 16,683 15,410 51,648 47,352 Sales and marketing 30,071 36,478 92,266 111,135 Research and development 29,315 28,544 87,738 82,484 General and administrative 19,633 20,240 58,182 61,105 Depreciation 3,566 4,483 11,011 13,231 Amortization 3,521 2,980 10,052 8,003 Total expenses 120,643 123,664 360,617 368,195 Operating loss (13,843 ) (32,045 ) (50,485 ) (106,901 ) Other expense, net (144 ) (47 ) (261 ) (39 ) Interest income, net 26 523 311 2,027 Total other (expense) income, net (118 ) 476 50 1,988 Loss before provision for income taxes (13,961 ) (31,569 ) (50,435 ) (104,913 ) Provision for income taxes (442 ) (372 ) (1,702 ) (1,326 ) Net loss $ (14,403 ) $ (31,941 ) $ (52,137 ) $ (106,239 ) Net loss per share attributable to common stockholders, basic and diluted $ (0.25 ) $ (0.58 ) $ (0.91 ) $ (1.96 ) Weighted-average common shares outstanding, basic and diluted 57,891,591 55,251,074 57,358,637 54,139,555 (1) Our potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. Phreesia, Inc. Consolidated Statements of Comprehensive Loss (Unaudited) (in thousands) Three months ended October 31, Nine months ended October 31, 2024 2023 2024 2023 Net loss $ (14,403 ) $ (31,941 ) $ (52,137 ) $ (106,239 ) Other comprehensive loss, net of tax: Change in foreign currency translation adjustments, net of tax (3 ) — (5 ) — Other comprehensive loss, net of tax (3 ) — (5 ) — Comprehensive loss $ (14,406 ) $ (31,941 ) $ (52,142 ) $ (106,239 ) Phreesia, Inc. Consolidated Statements of Cash Flows (Unaudited) (in thousands) Three months ended October 31, Nine months ended October 31, 2024 2023 2024 2023 Operating activities: Net loss $ (14,403 ) $ (31,941 ) $ (52,137 ) $ (106,239 ) Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Depreciation and amortization 7,087 7,463 21,063 21,234 Stock-based compensation expense 16,525 17,963 49,813 53,749 Amortization of deferred financing costs and debt discount 62 84 174 253 Cost of Phreesia hardware purchased by customers 571 582 1,248 1,232 Deferred contract acquisition costs amortization 1,322 235 1,706 855 Non-cash operating lease expense 207 142 568 484 Deferred taxes 57 39 176 181 Changes in operating assets and liabilities: Accounts receivable (10,141 ) (991 ) (6,558 ) (3,361 ) Prepaid expenses and other assets 1,005 (1,530 ) 4,286 (761 ) Deferred contract acquisition costs (552 ) — (765 ) — Accounts payable 6,948 1,189 5,198 (1,226 ) Accrued expenses and other liabilities (3,655 ) 469 (6,202 ) 6,530 Lease liabilities (202 ) (232 ) (622 ) (884 ) Deferred revenue 954 218 (1,823 ) (1,347 ) Net cash provided by (used in) operating activities 5,785 (6,310 ) 16,125 (29,300 ) Investing activities: Acquisitions, net of cash acquired — (10,406 ) — (14,279 ) Capitalized internal-use software (3,566 ) (4,069 ) (11,112 ) (13,889 ) Purchases of property and equipment (616 ) (1,242 ) (5,919 ) (3,344 ) Net cash used in investing activities (4,182 ) (15,717 ) (17,031 ) (31,512 ) Financing activities: Proceeds from issuance of common stock upon exercise of stock options 17 250 583 925 Treasury stock to satisfy tax withholdings on stock compensation awards — (1,451 ) — (12,176 ) Proceeds from employee stock purchase plan 840 919 2,443 2,782 Finance lease payments (1,895 ) (1,729 ) (5,170 ) (5,156 ) Constructive financing — — — 1,688 Principal payments on financing agreements (304 ) (273 ) (888 ) (318 ) Debt issuance costs and loan facility fee payments — — (152 ) (250 ) Financing payments of acquisition-related liabilities (309 ) — (1,673 ) — Net cash used in financing activities (1,651 ) (2,284 ) (4,857 ) (12,505 ) Effect of exchange rate changes on cash and cash equivalents (10 ) — (17 ) — Net decrease in cash and cash equivalents (58 ) (24,311 ) (5,780 ) (73,317 ) Cash and cash equivalents – beginning of period 81,798 127,677 87,520 176,683 Cash and cash equivalents – end of period $ 81,740 $ 103,366 $ 81,740 $ 103,366 Supplemental information of non-cash investing and financing information: Right of use assets acquired in exchange for operating lease liabilities $ — $ 346 $ 1,958 $ 346 Property and equipment acquisitions through finance leases $ 6,847 $ 371 $ 13,709 $ 7,438 Purchase of property and equipment and capitalized software included in current liabilities $ 3,508 $ 2,911 $ 3,508 $ 2,911 Capitalized stock-based compensation $ 343 $ 309 $ 1,006 $ 1,023 Issuance of stock to settle liabilities for stock-based compensation $ 2,853 $ 3,420 $ 10,679 $ 10,641 Issuance of stock as consideration in business combinations $ — $ 30,645 $ — $ 35,321 Deferred consideration liabilities payable in business combinations $ — $ 10,294 $ — $ 10,294 Capitalized software acquired through vendor financing $ — $ — $ — $ 2,047 Cash paid for: Interest $ 595 $ 295 $ 1,459 $ 649 Income taxes $ 549 $ — $ 2,559 $ 48 Non-GAAP Financial Measures This press release and statements made during the above-referenced webcast may include certain non-GAAP financial measures as defined by SEC rules. Adjusted EBITDA is a supplemental measure of our performance that is not required by, or presented in accordance with, GAAP. Adjusted EBITDA is not a measurement of our financial performance under GAAP and should not be considered as an alternative to net income or loss or any other performance measure derived in accordance with GAAP, or as an alternative to cash flows from operating activities as a measure of our liquidity. We define Adjusted EBITDA as net income or loss before interest income, net, provision for income taxes, depreciation and amortization, and before stock-based compensation expense and other expense, net. We have provided below a reconciliation of Adjusted EBITDA to net loss, the most directly comparable GAAP financial measure. We have presented Adjusted EBITDA in this press release and our Quarterly Report on Form 10-Q to be filed after this press release because it is a key measure used by our management and board of directors to understand and evaluate our core operating performance and trends, to prepare and approve our annual budget, and to develop short and long-term operational plans. In particular, we believe that the exclusion of the amounts eliminated in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core business. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and board of directors. We have not reconciled our Adjusted EBITDA outlook to GAAP Net income (loss) because we do not provide an outlook for GAAP Net income (loss) due to the uncertainty and potential variability of Other (income) expense, net and (Benefit from) provision for income taxes, which are reconciling items between Adjusted EBITDA and GAAP Net income (loss). Because we cannot reasonably predict such items, a reconciliation of the non-GAAP financial measure outlook to the corresponding GAAP measure is not available without unreasonable effort. We caution, however, that such items could have a significant impact on the calculation of GAAP Net income (loss). Our use of Adjusted EBITDA has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our financial results as reported under GAAP. Some of these limitations are as follows: Because of these and other limitations, you should consider Adjusted EBITDA along with other GAAP-based financial performance measures, including various cash flow metrics, net loss, and our GAAP financial results. The following table presents a reconciliation of Adjusted EBITDA to net loss for each of the periods indicated: Phreesia, Inc. Adjusted EBITDA ( Unaudited) Three months ended October 31, Nine months ended October 31, (in thousands) 2024 2023 2024 2023 Net loss $ (14,403 ) $ (31,941 ) $ (52,137 ) $ (106,239 ) Interest income, net (26 ) (523 ) (311 ) (2,027 ) Provision for income taxes 442 372 1,702 1,326 Depreciation and amortization 7,087 7,463 21,063 21,234 Stock-based compensation expense 16,525 17,963 49,813 53,749 Other expense, net 144 47 261 39 Adjusted EBITDA $ 9,769 $ (6,619 ) $ 20,391 $ (31,918 ) We calculate Free cash flow as Net cash provided by (used in) operating activities less capitalized internal-use software development costs and purchases of property and equipment. Additionally, Free cash flow is a supplemental measure of our performance that is not required by, or presented in accordance with, GAAP. We consider Free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by our business that can be used for strategic opportunities, including investing in our business, making strategic investments, partnerships and acquisitions and strengthening our financial position. The following table presents a reconciliation of Free cash flow from Net cash provided by (used in) operating activities, the most directly comparable GAAP financial measure, for each of the periods indicated: Phreesia, Inc. Free cash flow ( Unaudited) Three months ended October 31, Nine months ended October 31, (in thousands, unaudited) 2024 2023 2024 2023 Net cash provided by (used in) operating activities $ 5,785 $ (6,310 ) $ 16,125 $ (29,300 ) Less: Capitalized internal-use software (3,566 ) (4,069 ) (11,112 ) (13,889 ) Purchases of property and equipment (616 ) (1,242 ) (5,919 ) (3,344 ) Free cash flow $ 1,603 $ (11,621 ) $ (906 ) $ (46,533 ) Phreesia, Inc. Reconciliation of GAAP and Adjusted Operating Expenses (Unaudited) Three months ended October 31, Nine months ended October 31, (in thousands) 2024 2023 2024 2023 GAAP operating expenses General and administrative $ 19,633 $ 20,240 $ 58,182 $ 61,105 Sales and marketing 30,071 36,478 92,266 111,135 Research and development 29,315 28,544 87,738 82,484 Cost of revenue (excluding depreciation and amortization) 17,854 15,529 49,720 44,885 $ 96,873 $ 100,791 $ 287,906 $ 299,609 Stock compensation included in GAAP operating expenses General and administrative $ 6,049 $ 5,798 $ 18,534 $ 17,423 Sales and marketing 5,431 6,322 16,500 19,850 Research and development 3,793 4,561 11,049 13,002 Cost of revenue (excluding depreciation and amortization) 1,252 1,282 3,730 3,474 $ 16,525 $ 17,963 $ 49,813 $ 53,749 Adjusted operating expenses General and administrative $ 13,584 $ 14,442 $ 39,648 $ 43,682 Sales and marketing 24,640 30,156 75,766 91,285 Research and development 25,522 23,983 76,689 69,482 Cost of revenue (excluding depreciation and amortization) 16,602 14,247 45,990 41,411 $ 80,348 $ 82,828 $ 238,093 $ 245,860 Phreesia, Inc. Key Metrics (Unaudited) Three months ended October 31, Nine months ended October 31, 2024 2023 2024 2023 Key Metrics: Average number of healthcare services clients ("AHSCs") 4,237 3,688 4,157 3,481 Healthcare services revenue per AHSC $ 17,481 $ 17,845 $ 53,351 $ 54,836 Total revenue per AHSC $ 25,207 $ 24,842 $ 74,605 $ 75,063 The definitions of our key metrics are presented below. Additional Information (Unaudited) Three months ended October 31, Nine months ended October 31, 2024 2023 2024 2023 Patient payment volume (in millions) $ 1,081 $ 965 $ 3,340 $ 2,970 Payment facilitator volume percentage 81 % 82 % 81 % 82 % ______________________________ 1 Adjusted EBITDA is a non-GAAP measure. We define Adjusted EBITDA as net income or loss before interest income, net, provision for income taxes, depreciation and amortization, and before stock-based compensation expense and other expense, net. See “Non-GAAP Financial Measures” for a reconciliation of Adjusted EBITDA to the closest GAAP measure. 2 Free cash flow is a non-GAAP measure. We define Free cash flow as net cash provided by (used in) operating activities less capitalized internal-use software development costs and purchases of property and equipment. See “Non-GAAP Financial Measures” for a reconciliation of Free cash flow to the closest GAAP measure. 3 We define “profitability,” discussed herein, in terms of Adjusted EBITDA, a non-GAAP financial measure. See ‘Non-GAAP Financial Measures’ for a definition of Adjusted EBITDA and a reconciliation of our Adjusted EBITDA to Net loss, the closest GAAP measure. View source version on businesswire.com : https://www.businesswire.com/news/home/20241209683231/en/ CONTACT: Investor Relations Contact:Balaji Gandhi Phreesia, Inc. investors@phreesia.com (929) 506-4950Media Contact:Nicole Gist Phreesia, Inc. nicole.gist@phreesia.com (407) 760-6274 KEYWORD: DELAWARE UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: SCIENCE SOFTWARE PRACTICE MANAGEMENT RESEARCH HEALTH HOSPITALS HEALTH TECHNOLOGY TECHNOLOGY SOURCE: Phreesia, Inc. Copyright Business Wire 2024. PUB: 12/09/2024 04:05 PM/DISC: 12/09/2024 04:05 PM http://www.businesswire.com/news/home/20241209683231/en

KUALA LUMPUR, Malaysia, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Graphjet Technology ("Graphjet" or "the Company") GTI , a leading developer of patented technologies to produce graphite and graphene directly from agricultural waste, today announced that management will host a webcast and conference call to provide a business update at 9 AM ET on Thursday, December 12, 2024. A live webcast of the call will be available by clicking here . Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may also access the call by dialing (877) 407-9208 for domestic callers or (201) 493-6784 for international callers. A replay of the call will be available for two weeks by dialing (844) 512-2921 for domestic callers or (412) 317-6671 for international callers and using Conference ID: 13750405. The archived webcast will be available in the Investor Relations section of the Company's website. About Graphjet Technology Sdn. Bhd. Graphjet Technology Sdn. Bhd. GTI was founded in 2019 in Malaysia as an innovative graphene and graphite producer. Graphjet Technology has the world's first patented technology to recycle palm kernel shells generated in the production of palm seed oil to produce single layer graphene and artificial graphite. Graphjet's sustainable production methods utilizing palm kernel shells, a waste agricultural product that is common in Malaysia, will set a new shift in graphite and graphene supply chain of the world. For more information, please visit https://www.graphjettech.com/ . Graphjet Technology Contacts Investors GraphjetIR@icrinc.com Media GraphjetPR@icrinc.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

NoneVodafone Idea share will be in focus on Tuesday after the company’s board approved the issuance of up to 175.53 crore equity shares worth Rs 1,980 crore on a preferential basis. The shares will be issued at a price of Rs 11.25 per share, which is a premium of 39% to Monday's closing price and modestly higher than the FPO price of Rs 11 per share. The shares aggregating up to Rs 1,280 crore will be issued to Omega Telecom Holdings Private Limited while worth Rs 700 crore to Usha Martin Telematics Limited. Both are Vodafone Group entities and promoters of the company. Omega Telecom Holdings held 0.40% stake in Vodafone as on September 30, 2024 while Usha Martin's stake stood at 0.13%. Stock Trading Derivative Analytics Made Easy By - Vivek Bajaj, Co Founder- Stockedge and Elearnmarkets View Program Stock Trading Technical Analysis Made Easy: Online Certification Course By - Souradeep Dey, Equity and Commodity Trader, Trainer View Program Stock Trading Options Scalping Made Easy By - Sivakumar Jayachandran, Ace Scalper View Program Stock Trading Stock Investing Made Easy: Beginner's Stock Market Investment Course By - elearnmarkets, Financial Education by StockEdge View Program Stock Trading Technical Analysis Demystified: A Complete Guide to Trading By - Kunal Patel, Options Trader, Instructor View Program Stock Trading Technical Analysis for Everyone - Technical Analysis Course By - Abhijit Paul, Technical Research Head, Fund Manager- ICICI Securities View Program Stock Trading RSI Trading Techniques: Mastering the RSI Indicator By - Dinesh Nagpal, Full Time Trader, Ichimoku & Trading Psychology Expert View Program Stock Trading Stock Valuation Made Easy By - Rounak Gouti, Investment commentary writer, Experience in equity research View Program Stock Trading Markets 102: Mastering Sentiment Indicators for Swing and Positional Trading By - Rohit Srivastava, Founder- Indiacharts.com View Program Stock Trading Advanced Strategies in Stock Market Mastery By - CA Raj K Agrawal, Chartered Accountant View Program Stock Trading Complete Guide to Stock Market Trading: From Basics to Advanced By - Harneet Singh Kharbanda, Full Time Trader View Program Stock Trading Renko Chart Patterns Made Easy By - Kaushik Akiwatkar, Derivative Trader and Investor View Program Stock Trading RSI Made Easy: RSI Trading Course By - Souradeep Dey, Equity and Commodity Trader, Trainer View Program The stock was recently in news after UK-based telecom operator Vodafone PLC announced its intention to sell a 3% stake in Indus Towers to settle a $101 million (approximately Rs 856 crore) debt and use the remaining proceeds to support its Indian venture, Vodafone Idea. It sold its entire remaining through a series of block deals with prominent global investment banks, alternative asset managers, large overseas fund houses, hedge funds, local mutual funds, and pension funds, raising around Rs 2,801.7 crore. This move completes Vodafone’s exit from the Indian tower company, which is now a subsidiary of Bharti Airtel . Vodafone Idea narrowed its losses to Rs 7,176 crore in the September quarter of FY25, compared with Rs 8,738 crore in the same quarter of last year. Revenue from operations in the reporting period rose marginally by 2% year-on-year (YoY) to Rs 10,932 crore. On a sequential basis, loss has widened from Rs 6432 crore posted in the preceding June quarter. Meanwhile, revenues improved 4% quarter-on-quarter, aided by the recent tariff hikes undertaken by all private operators. EBITDA for the quarter increased to Rs 4550 crore in the reporting quarter. This compares with Rs 4283 crore in the last year quarter. Cash EBITDA excluding Ind AS 116 impact improved to Rs 2320 crore, highest since the merger, growing by 10% QoQ. Also Read: Torrent Power raises Rs 3,500 crore in maiden QIP On Monday, Vodafone Idea shares closed at Rs 8.1, down 0.25% on the BSE, while the benchmark Sensex declined 0.25%. The stock has dropped 49% in the past six months and over 52% year-to-date, with the company’s market capitalization now at Rs 56,456 crore. ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times) (You can now subscribe to our ETMarkets WhatsApp channel )Two years ago, as baseball’s winter meetings approached, Justin Verlander was one of the hottest names on the free-agent market. Weeks earlier, the ultra-accomplished right-hander had added yet another accolade to his collection when he won the 2022 AL Cy Young Award unanimously, becoming the 11th pitcher in MLB history to win three Cy Youngs. Not only had he delivered a sparkling campaign in his first year back from Tommy John surgery, but he had also done so at age 39, making him the to claim the game’s top pitching prize. And if his individual triumphs weren’t enough, Verlander’s Astros had just won the World Series. Such a sensational season at such an advanced age made Verlander an especially unique free agent following the expiration of his Astros contract. Still seemingly at the top of his craft, Verlander deserved a significant payday. But for a pitcher who was about to turn 40, it seemed likely that such a deal would come in the form of a shorter-term pact with a massive average annual value. Sure enough, the 2022 winter meetings in San Diego started with the New York Mets signing Verlander to a two-year, $86.66 million deal — one with a nearly identical $43.3M AAV to the three-year, $130M contract the Mets gave fellow future Hall of Fame right-hander Max Scherzer the winter prior. Signing Verlander was one of several huge expenditures for the Mets that offseason, as they also spent big to retain Edwin Diaz and Brandon Nimmo, in addition to signing Japanese right-hander Kodai Senga to a $75M deal. But the active offseason failed to translate to results the next season, prompting the Mets to dramatically deconstruct their roster at the 2023 trade deadline, including sending Verlander back to the Astros, ending his stint in Queens prematurely. It was a tenure further abbreviated by a spring training shoulder injury that forced Verlander to miss the first month of the season, meaning he made only 16 starts for New York — a stunningly small total considering the titanic contract the team had given him months earlier. As a 40-year-old in 2023, Verlander didn't pitch at a Cy Young level for the Mets or the Astros, but he was still an above-average starter once he returned from injury. While his fastball velocity had dropped a tick and his strikeout rate declined considerably, from 27.8% in 2022 to 21.5% in 2023, his stellar run prevention was intact: Verlander’s 3.22 ERA ranked . He also acquitted himself well in the postseason during Houston’s run to another ALCS (2.95 ERA in 18 1/3 innings), expanding his lengthy playoff résumé with three more solid October outings. Back for his age-41 season and the second year of his lucrative contract, shoulder issues again delayed the start to Verlander’s 2024 season, this time for a couple of weeks. He posted a 3.95 ERA across 10 starts before a neck injury sent him back to the injured list, where he joined a litany of Astros arms on the shelf. He returned in late August but struggled down the stretch, to the tune of an 8.10 ERA across 33 1/3 innings of work. Verlander’s poor form did not ultimately cost Houston in the standings, but it certainly damaged his prospects of cracking the playoff rotation as the Astros prepared for October. Verlander’s final start of the season came on Saturday, Sept. 28, in Cleveland in what turned out to be Houston’s final regular-season game of 2024, as Game 162 on Sunday was rained out. The final line — six innings, seven hits, three runs allowed, zero walks, five strikeouts — was hardly anything special, particularly by Verlander’s lofty standards. But it was comfortably his best outing since his return from the neck injury and an encouraging sign after a trying few months. "It's probably the best I've felt since coming back so far,” Verlander said afterward. His secondary stuff was sharp that day, as he threw a higher percentage of sliders and changeups than he had in any other start all season. His fastball , his hardest pitch since returning from injury and tied for his second-hardest pitch of the season. He threw 74% of his 95 pitches for strikes, his highest rate of the season. And it was just the second start all season in which he did not walk or hit a batter, with the other such outing coming in his first start of the season on April 19. “I'm somebody who tries to be realistic with myself, and I know I haven't been nearly as good as I need to be,” Verlander said of his struggles leading up to his regular-season finale. “I didn't have the luxury of time. I had to come back and try to figure this thing out and pitch. The only way you can find out where you're at is by pitching. And it's been tough, but slowly gaining on it. “I also know there's been some bad luck mixed in there, but, you know, I'm not going to let that be a crutch and say, ‘No, it's just that.’ It's not — I haven't been as sharp as I needed to be. But I feel like I've been inching in the right direction.” Earlier that week, the Astros had completed their epic chase-down of the Mariners and clinched another division crown, meaning that game had minimal stakes for either team. But for Verlander, still searching for something resembling his ace self, the outing carried significant weight, as it represented another opportunity to remind himself and the rest of the baseball world what he's capable of. “To be frank, I wish this wasn't the end of the season,” Verlander reflected further. “With somebody, myself, who works as hard as I possibly can to figure it out ... usually there's something I can get to click, like, ‘All right, that's it.’ But this injury has been a little bit different than that. It's just been a little off, and there's been nothing making it click. So it's been inching in the right direction. This would be nice to build off of.” Had the Astros advanced past Detroit in the wild-card round, Verlander might have been added to the ALDS roster, perhaps giving him the chance to build on the momentum from his final regular-season start. Instead, the Tigers upset the Astros in Houston, ending the Astros’ streak of seven consecutive trips to the ALCS and initiating Verlander’s free agency earlier than expected. "You never know what's gonna happen,” Verlander said after his start in Cleveland about the possibility of it being his final outing as an Astro. “But I've got some work to do this offseason personally. So that's kind of where my focus is at. And then if I end up back here, great. Love Houston, love the people, love my teammates. I've had an incredible run. "If not, will tip my cap and say thank you for an incredible journey.” While Verlander finished on a strong individual note in September, it was a far cry from his previous foray into free agency. Things are very different now. His name has spent scarce time in the headlines over the first month-plus of the hot stove season. Perhaps that will begin to change . He’s likely to sign a one-year deal with a contender, but so far, we’ve heard little beyond the expected dialogue between Verlander in Houston — fairly standard protocol for any free agent in the early stages of the winter. Verlander is hardly alone in his relative exclusion from such discussions across the industry; Juan Soto , with to interrupt the historic pursuit of the 26-year-old outfielder. But as a future Hall of Famer who firmly believes he still has something to offer major-league teams, Verlander’s free agency is unquestionably one of the more fascinating subplots of this winter. And while Cooperstown is sure to call at some point down the line, the ending of his illustrious career has yet to be written. Whether he stays in Houston or starts a new chapter elsewhere, Verlander will be attempting to defy the age limits historically imposed on his position. Since the turn of the century, have stayed in a big-league rotation for most or all of an MLB season at age-42 or older, and very few of them have been especially effective. The iconic Hall of Fame Braves trio of Greg Maddux, John Smoltz and Tom Glavine all pitched the final seasons of their careers at age 42, with only Maddux making it through a full year healthy and none of them posting an above-average ERA. Randy Johnson made 33 starts in his age-42 season with the Yankees in 2006 and delivered three more solid campaigns after that, but none resembled that of a frontline arm. Roger Clemens, whose late-career excellence has been notoriously tarnished by his connection to performance-enhancing drugs, is the only example this century of true dominance at such an advanced age: He finished third in AL Cy Young voting as a 42-year-old in 2005 and pitched well in two seasons after that. Beyond those legends, a quartet of lefties stuck around and started games into their 40s: David Wells, Kenny Rogers, Jamie Moyer and, most recently, Rich Hill, none of whom provided above-average run prevention after turning 42. The same can be said about knuckleballers Tim Wakefield and R.A. Dickey, and their rare skillset made them obvious outliers. Finally, there’s Bartolo Colon, whose All-Star campaign with the Mets in 2016 was arguably the best non-Clemens age-42-or-older season among these dozen arms but who fell off after that in his final two years as a big-league starter (6.13 ERA). These examples of largely ineffective older pitchers demonstrate the challenge ahead for Verlander. After his tremendous Cy Young season at age 39, it seemed reasonable to expect him to continue to pitch well into his mid-40s, and he regularly spoke of his intention to do so. This past year might've put a damper on those ambitions, but it’s too early to say that dream is entirely dead. While there’s little left for Verlander to prove, he remains resolute that he has . Three hundred wins (he’s at 262 right now), but he’s just 84 strikeouts away from becoming the 10th pitcher in MLB history to reach 3,500 Ks. And, of course, there are always more championships to chase. If his health cooperates — a big if — maybe he can build off his strong finish to 2024 and make the necessary adjustments to become a reliable rotation option again. His Cy Young-caliber days might be behind him, but a lot of teams would happily pay for the version of Verlander we saw in 2023. Whichever team that ends up being, the contract is sure to be a fraction of what Verlander received two winters ago. But no matter his salary or what jersey he’s wearing, Verlander’s 2025 will be one of the more intriguing campaigns to watch — to see whether he defies his age once again or succumbs to the same struggles as his 42-and-up predecessors.

NEW YORK (AP) — A slide for market superstar Nvidia helped pull U.S. stock indexes down from their records. The S&P 500 fell 0.6% Monday, coming off its 57th all-time high of the year so far. The Dow Jones Industrial Average fell 0.5%, and the Nasdaq composite dropped 0.6% from its own record. Nvidia was the market’s heaviest weight after China said it’s probing the chip giant for potential antitrust violations. Stocks in Hong Kong jumped after top Chinese leaders agreed on a “moderately loose” monetary policy. Prices for oil and gold rose following the ouster of Syrian leader Bashar Assad. THIS IS A BREAKING NEWS UPDATE. AP’s earlier story follows below. NEW YORK (AP) — A slide for market superstar Nvidia on Monday is helping to pull U.S. stock indexes down from their records. The S&P 500 fell by 0.3% in afternoon trading, coming off its 57th all-time high of the year so far. The Dow Jones Industrial Average was down 57 points, or 0.1%, as of 1:53 p.m. Eastern time, and the Nasdaq composite pulled back 0.3% from its own record. Nvidia's drop of 2.1% was by far the heaviest weight on the S&P 500 after China said it's investigating the company over suspected violations of Chinese anti-monopoly laws. Nvidia has skyrocketed to become one of Wall Street’s most valuable companies because its chips are driving much of the world’s move into artificial-intelligence technology. That gives its stock’s movements more sway on the S&P 500 than nearly every other. Nvidia's fall overshadowed gains in Hong Kong and for Chinese stocks trading in the United States on hopes that China will deliver more stimulus for the world's second-largest economy. Roughly half the stocks in the S&P 500 also rose. The week’s highlight for Wall Street will arrive midweek when the latest updates on inflation arrive. Economists expect Wednesday’s report to show the inflation that U.S. consumers are feeling remained stuck at roughly the same level last month. A separate report on Thursday, meanwhile, could show an acceleration in inflation at the wholesale level. They’re the last big pieces of data the Federal Reserve will get before its meeting next week on interest rates. The widespread expectation is still that the central bank will cut its main interest rate for the third time this year. The Fed has been easing its main interest rate from a two-decade high since September to offer more help for the slowing job market, after bringing inflation nearly all the way down to its 2% target. Lower interest rates can ease the brakes off the economy, but they can also offer more fuel for inflation. Expectations for a series of cuts from the Fed have been a major reason the S&P 500 has set so many all-time highs this year. On Wall Street, Interpublic Group rose 5.8% after rival Omnicom said it would buy the marketing and communications firm in an all-stock deal. The pair had a combined revenue of $25.6 billion last year. Omnicom, meanwhile, sank 9.3%. Macy’s climbed 1.5% after an activist investor, Barington Capital Group, called on the retailer to buy back at least $2 billion of its own stock over the next three years and make other moves to help boost its stock price. Super Micro Computer rose 4.6% after saying it got an extension that will keep its stock listed on the Nasdaq through Feb. 25, as it works to file its delayed annual report and other required financial statements. Earlier this month, the maker of servers used in artificial-intelligence technology said an investigation found no evidence of misconduct by its management or by the company’s board following the resignation of its public auditor . In the oil market, a barrel of benchmark U.S. crude rallied 2% to $68.56 following the overthrow of Syrian leader Bashar Assad, who sought asylum in Moscow after rebels. Brent crude, the international standard, was mostly unchanged at $71.05. The price of gold also rose 1% amid the uncertainty created by the end of the Assad family’s 50 years of iron rule. In stock markets abroad, the Hang Seng jumped 2.8% in Hong Kong after top Chinese leaders agreed on a “moderately loose” monetary policy for the world’s second-largest economy. That’s a shift away from a more cautious, “prudent” stance for the first time in 10 years. A major planning meeting later this week could also bring more stimulus for the Chinese economy. U.S.-listed stocks of several Chinese companies climbed, such as a 13.1% jump for electric-vehicle company Nio and a 9.1% rise for Alibaba Group. Stocks in Shanghai, though, were roughly flat. In Seoul, South Korea’s Kospi slumped 2.8% as the fallout continues from President Yoon Suk Yeol 's brief declaration of martial law last week in the midst of a budget dispute. In the bond market, the yield on the 10-year Treasury rose to 4.19% from 4.15% late Friday. ___ AP Business Writers Matt Ott and Elaine Kurtenbach contributed. Stan Choe, The Associated PressGermany to make migrant smuggling to UK a clear criminal offence

Ruben Amorim impressed with Arsenal’s corners after first defeat as Man Utd boss

DETROIT (AP) — For most of a century, the Detroit Lions making the playoffs was a banner day. Suddenly, it has become old hat. After winning their last NFL championship in 1957 , the Lions only played 13 playoff games in the next 75 seasons. They only won one of them — a 38-6 rout of the Dallas Cowboys in 1991. That all changed last season. The Lions beat the Rams 24-23 on Jan. 14 and then defeated Tampa Bay 31-23 a week later. They led the NFC championship game 24-7 at halftime, but the San Francisco 49ers rallied to win 34-31. This year, things have been even better. A week after a Thanksgiving win over the Chicago Bears, the Lions beat Green Bay 34-31 to move to 12-1 and clinch a second straight postseason berth — the first time they've done that since going three years in a row from 1993-95. Coach Dan Campbell didn't even notice his team had secured a playoff spot after beating the Packers. “I just found that out — I didn't even realize,” he said after the game. “It's good. It's good, but it's like, man, we've got four (games) left and we want to get in a different way. We want to go in on our terms and find a way to get this one seed. That's the priority.” Campbell was so oblivious to locking up a spot that he didn't even mention it to the team after the game — although they might have seen “Playoffs Clinched” plastered all over the scoreboards. “I wish I had told the team, but I had no idea,” he said. “Honestly, I think they know. They feel like I feel. We can do the old golf clap, but we know what we want to do.” Jared Goff, who followed Campbell into the interview room, agreed with his coach. “I just heard that,” he said. “It's pretty cool, but it is certainly not what our ultimate goal is. We want to win this division, and we've still got some work to do.” At 12-1 and on an 11-game winning streak, it is hard to find something that isn't working. The Lions offense, though, has been remarkable. They have scored at least 23 points in 10 straight games, including six games over 30, four over 40 and two over 50. They are leading the league in scoring at 32.1 points per game and are fourth in both passing touchdowns (27) and rushing touchdowns (22). The Lions are second in the league in scoring defense (18.0 ppg), but injuries are starting to catch up to them. Jordan Love averaged 10.3 yards per attempt and 17.2 yards per completion on Thursday — both season-worsts for Detroit's defense — and the Packers were the first team this season to score 30 points against them. Seven Lions defenders registered a quarterback hit on Thursday night. Linebacker Jack Campbell was a first-round pick in 2023 and has been a fixture on the Detroit defense, but the other six — Al-Quadin Muhammad, Myles Adams, Trevor Nowaske, Za'Darius Smith, Ezekiel Turner and Jonah Williams — have joined the team during the regular season to replace injured players. Rookie CB Terrion Arnold had a rough day, including yet another pass-interference penalty in the end zone, this one wiping out a Lions interception. He hasn't recorded an interception in his 12-game career and is averaging 0.6 passes defended per game. The Lions were missing 11 defensive linemen and linebackers against the Packers, then lost key defensive tackle Alim McNeill to a head injury. Most of those players are on injured reserve, but it isn't clear if McNeill, Levi Onwuzurike (hamstring), Josh Paschal (knee) or D.J. Reader (shoulder) will be available to face Buffalo on Dec. 15. 18 — the number of Lions on injured reserve, more than any other team in the NFL. If anything can derail them between now and the Super Bowl, it is going to be running out of healthy players in places other than the defensive front seven. Get as much rest and healing as possible with a long week ahead. ___ AP NFL: https://apnews.com/hub/nflANKENY, Iowa (AP) — ANKENY, Iowa (AP) — Casey's General Stores Inc. (CASY) on Monday reported fiscal second-quarter net income of $180.9 million. The Ankeny, Iowa-based company said it had net income of $4.85 per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for earnings of $4.24 per share. The convenience store chain posted revenue of $3.95 billion in the period, which missed Street forecasts. Five analysts surveyed by Zacks expected $4.01 billion. Casey's shares have risen 52% since the beginning of the year. In the final minutes of trading on Monday, shares hit $418.24, a climb of 52% in the last 12 months. This story was generated by Automated Insights ( http://automatedinsights.com/ap ) using data from Zacks Investment Research. Access a Zacks stock report on CASY at https://www.zacks.com/ap/CASY

With Trump on the way, advocates look to states to pick up medical debt fight

Universal Corporation Receives NYSE Notice Regarding Filing of Form 10-Q for the Fiscal Quarter Ended September 30, 2024

3D Systems Reports Third Quarter 2024 Financial ResultsMartin Madaus Elected to Hologic Board of Directors

Casey's: Fiscal Q2 Earnings Snapshot